Dr. Yaqoub Ashhab, a researcher at Palestine Korea Biotechnology Center, affiliated to the Deanship of Scientific Research and Graduate Studies at Palestine Polytechnic University, participated in publishing a scientific research with an international group of researchers from the University of Toronto, Italy, and the Vaccine Research Institute, affiliated to GlaxoSmithKline-Vaccines. The research has been published in one of the global reputed journals, Journal of Extracellular Vesicles, in the field of medical science research. This journal has a very distinctive impact factor: 15.
The research focused on developing a new method to improve the effectiveness of vaccines, or known as "vaccines", and make these vaccines safer, whether these are preventative vaccines that work against viruses or bacteria, or even curative vaccines for some types of cancerous tumors. Recently, there is an increase interest in this trend as a new method in promoting cancer treatment.
It is worth noting here that the research team, consisting of "17" researchers, and headed by Professor "Guido Grandi", was able within "6" years to use the "Computational Biology" and "Synthetic Biology" technique to make fundamental modifications in the genome of the bacterium E.Coli, so that the modified bacteria could have a high ability to produce vesicles with distinctive immune characteristics. The bacteria has been genetically modified to conform to the health and safety standards of the European Medicines Agency. The team used these vesicles as a tool to carry and deliver many products and prove their superior ability in developing vaccines against a different group of microbes, in addition to using them in one of the samples of experimental therapeutic cancer vaccines.